Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GBIO NASDAQ:LVTX NASDAQ:PCSA NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBIOGeneration Bio$6.25-0.3%$5.68$3.00▼$25.70$42.09M2.53153,723 shs20,140 shsLVTXLAVA Therapeutics$1.61-0.2%$1.54$0.85▼$2.09$42.25M0.5224,037 shs25,862 shsPCSAHeatwurx$0.34+20.1%$0.21$0.15▼$1.50$16.87M1.538.83 million shs178.45 million shsXLOXilio Therapeutics$0.82-0.3%$0.72$0.62▼$1.70$42.60M-0.071.85 million shs360,154 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBIOGeneration Bio-1.10%+4.85%+4.67%+77.67%-74.72%LVTXLAVA Therapeutics+0.63%0.00%+2.55%+18.65%-5.85%PCSAHeatwurx+30.86%+39.78%+62.40%+31.36%-76.55%XLOXilio Therapeutics+0.81%-4.46%+17.83%+16.11%+5.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBIOGeneration Bio$6.25-0.3%$5.68$3.00▼$25.70$42.09M2.53153,723 shs20,140 shsLVTXLAVA Therapeutics$1.61-0.2%$1.54$0.85▼$2.09$42.25M0.5224,037 shs25,862 shsPCSAHeatwurx$0.34+20.1%$0.21$0.15▼$1.50$16.87M1.538.83 million shs178.45 million shsXLOXilio Therapeutics$0.82-0.3%$0.72$0.62▼$1.70$42.60M-0.071.85 million shs360,154 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBIOGeneration Bio-1.10%+4.85%+4.67%+77.67%-74.72%LVTXLAVA Therapeutics+0.63%0.00%+2.55%+18.65%-5.85%PCSAHeatwurx+30.86%+39.78%+62.40%+31.36%-76.55%XLOXilio Therapeutics+0.81%-4.46%+17.83%+16.11%+5.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGBIOGeneration Bio 2.25Hold$10.6770.67% UpsideLVTXLAVA Therapeutics 1.86Reduce$2.6967.19% UpsidePCSAHeatwurx 2.00Hold$1.00198.51% UpsideXLOXilio Therapeutics 2.75Moderate Buy$3.00264.96% UpsideCurrent Analyst Ratings BreakdownLatest PCSA, GBIO, XLO, and LVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025GBIOGeneration BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LVTXLAVA TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PCSAHeatwurxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XLOXilio TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/2/2025PCSAHeatwurxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.00 ➝ $1.008/26/2025PCSAHeatwurxZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025GBIOGeneration BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.008/13/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $7.008/13/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/6/2025XLOXilio TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025XLOXilio TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$2.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGBIOGeneration Bio$21.23M1.98N/AN/A$12.91 per share0.48LVTXLAVA Therapeutics$11.98M3.53N/AN/A$1.06 per share1.52PCSAHeatwurxN/AN/AN/AN/A$0.46 per shareN/AXLOXilio Therapeutics$6.34M6.72N/AN/A$0.40 per share2.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGBIOGeneration Bio-$131.67M-$10.82N/AN/AN/A-341.12%-91.07%-33.65%11/5/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%12/9/2025 (Estimated)PCSAHeatwurx-$11.85M-$2.32N/AN/AN/AN/A-342.36%-243.48%10/29/2025 (Estimated)XLOXilio Therapeutics-$58.24M-$0.76N/AN/AN/A-374.79%-399.15%-58.68%11/6/2025 (Estimated)Latest PCSA, GBIO, XLO, and LVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025PCSAHeatwurx-$0.08N/AN/AN/AN/AN/A8/14/2025Q2 2025XLOXilio Therapeutics-$0.08-$0.16-$0.08-$0.16$8.21 million$8.21 million8/13/2025Q2 2025LVTXLAVA Therapeutics-$0.28-$0.32-$0.04-$0.32N/AN/A8/12/2025Q2 2025GBIOGeneration Bio-$2.80-$3.12-$0.32-$3.12$2.51 million$0.77 million8/7/2025Q2 2025PCSAHeatwurx-$0.23-$0.25-$0.02-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGBIOGeneration BioN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGBIOGeneration BioN/A7.517.51LVTXLAVA TherapeuticsN/A10.7810.78PCSAHeatwurxN/A3.453.45XLOXilio TherapeuticsN/A2.322.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGBIOGeneration Bio95.22%LVTXLAVA TherapeuticsN/APCSAHeatwurx91.93%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipGBIOGeneration Bio21.80%LVTXLAVA Therapeutics9.50%PCSAHeatwurx2.40%XLOXilio Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGBIOGeneration Bio1506.74 million5.31 millionOptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionablePCSAHeatwurx2050.35 million49.14 millionNot OptionableXLOXilio Therapeutics7051.83 million48.56 millionNot OptionablePCSA, GBIO, XLO, and LVTX HeadlinesRecent News About These CompaniesXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingOctober 3, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | globenewswire.comXilio Therapeutics sees cash runway into 1Q27September 9, 2025 | msn.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under ...September 9, 2025 | finance.yahoo.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with GileadSeptember 9, 2025 | globenewswire.comXilio Therapeutics (XLO) Has a New Rating from Leerink PartnersAugust 29, 2025 | theglobeandmail.comXilio Therapeutics Faces Nasdaq Equity Compliance ChallengeAugust 28, 2025 | tipranks.comXLO | Xilio Therapeutics Inc. Annual Cash Flow Statement | MarketWatchAugust 16, 2025 | marketwatch.comXilio Therapeutics reports Q2 EPS (16c) vs (24c) last yearAugust 15, 2025 | msn.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 15, 2025 | taiwannews.com.twTXilio Revenue Jumps 246 Percent in Q2August 15, 2025 | aol.comAXilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue EstimatesAugust 14, 2025 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform RecommendationAugust 7, 2025 | msn.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comJames Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockJune 19, 2025 | insidertrades.comXilio Therapeutics expands board, elects new directorJune 12, 2025 | investing.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of DirectorsJune 10, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCSA, GBIO, XLO, and LVTX Company DescriptionsGeneration Bio NASDAQ:GBIO$6.25 -0.02 (-0.32%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.LAVA Therapeutics NASDAQ:LVTX$1.61 0.00 (-0.25%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Heatwurx NASDAQ:PCSA$0.34 +0.06 (+20.07%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.Xilio Therapeutics NASDAQ:XLO$0.82 0.00 (-0.32%) As of 02:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal 2 Defense Stocks Riding 2025’s Massive Momentum Wave Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
